Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RLX030 renal hemodynamics study in chronic heart failure
NL-OMON38100Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Dec 2011
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic heart failure (CHF) comparing Serelaxin with Placebo (2 arms). Primary endpoints: Renal blood flow and Glomerular filtration rate. Started Dec 2011; status: active, not recruiting.
02
Drugs
serelaxin
03
Conditions
chronic heart failure (CHF)
Beyond the preview
Go deeper on NL-OMON38100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38100.